Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 12/2009

01-12-2009 | Original Article

Wilms’ tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome

Authors: Antonia Busse, Nicola Gökbuget, Jan Michael Siehl, Dieter Hoelzer, Stefan Schwartz, Anika Rietz, Eckhard Thiel, Ulrich Keilholz

Published in: Annals of Hematology | Issue 12/2009

Login to get access

Abstract

Wilms’ tumor gene 1 (WT1) is gaining increasing attention as a therapeutic target molecule due to its common expression in acute leukemias and its involvement in cell proliferation. Here, we reported on WT1 messenger RNA expression levels at diagnosis in a series of 238 adult acute lymphoblastic leukemia (ALL) samples of various subtypes and clinical outcome. WT1 expression was found in 219 out of 238 ALL samples (92%). Compared to a cohort of acute myeloid leukemia patients, the median WT1 expression level in ALL was significantly lower with large variations among different ALL subgroups. Specifically, WT1 expression levels were low in mature B-ALL and highest in ALL cases with co-expression of myeloid markers, making it a useful therapeutic target molecule in adult ALL with the exception of mature B-ALL. Cox regression analysis, considering ALL phenotype as well as molecular-cytogenetic subsets, revealed no independent prognostic role of WT1 expression level for disease-free and overall survival.
Literature
1.
Haber DA, Housman DE (1992) Role of the WT1 gene in Wilms’ tumour. Cancer Surv 12:105–117PubMed
2.
Hohenstein P, Hastie ND (2006) The many facets of the Wilms’ tumour gene, WT1. Hum Mol Genet 15(Spec No 2):R196–R201CrossRefPubMed
3.
4.
Pritchard-Jones K (1999) The Wilms tumour gene, WT1, in normal and abnormal nephrogenesis. Pediatr Nephrol 13(7):620–625PubMed
5.
6.
Maurer U, Brieger J, Weidmann E et al (1997) The Wilms’ tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 25(9):945–950PubMed
7.
8.
Algar EM, Khromykh T, Smith SI et al (1996) A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 12(5):1005–1014PubMed
9.
Inoue K, Tamaki H, Ogawa H et al (1998) Wilms’ tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 91(8):2969–2976PubMed
10.
Yamagami T, Sugiyama H, Inoue K et al (1996) Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87(7):2878–2884PubMed
11.
12.
13.
14.
15.
Menssen HD, Renkl HJ, Rodeck U et al (1995) Presence of Wilms’ tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9(6):1060–1067PubMed
16.
Miwa H, Beran M, Saunders GF (1992) Expression of the Wilms’ tumor gene (WT1) in human leukemias. Leukemia 6(5):405–409PubMed
17.
Inoue K, Ogawa H, Sonoda Y et al (1997) Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89(4):1405–1412PubMed
18.
Baird PN, Simmons PJ (1997) Expression of the Wilms’ tumor gene (WT1) in normal hemopoiesis. Exp Hematol 25(4):312–320PubMed
19.
Inoue K, Ogawa H, Yamagami T et al (1996) Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 88(6):2267–2278PubMed
20.
Cilloni D, Saglio G (2004) WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 112(1–2):79–84. doi:10.​1159/​000077562 CrossRefPubMed
21.
Tamaki H, Mishima M, Kawakami M et al (2003) Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int J Hematol 78(4):349–356. doi:10.​1007/​BF02983561 CrossRefPubMed
22.
Cilloni D, Gottardi E, De Micheli D et al (2002) Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16(10):2115–2121. doi:10.​1038/​sj.​leu.​2402675 CrossRefPubMed
23.
Inoue K, Sugiyama H, Ogawa H et al (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84(9):3071–3079PubMed
24.
Omran HA, Shabani M, Vossough P et al (2008) Cross-sectional monitoring of Wilms’ tumor gene 1 (WT1) expression in Iranian patients with acute lymphoblastic leukemia at diagnosis, relapse and remission. Leuk Lymphoma 49(2):281–290. doi:10.​1080/​1042819070178470​6 CrossRefPubMed
25.
26.
Boublikova L, Kalinova M, Ryan J et al (2006) Wilms’ tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 20(2):254–263. doi:10.​1038/​sj.​leu.​2404047 CrossRefPubMed
27.
28.
Siehl JM, Thiel E, Heufelder K et al (2003) Possible regulation of Wilms’ tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias. Br J Haematol 123(2):235–242. doi:10.​1046/​j.​1365-2141.​2003.​04622.​x CrossRefPubMed
29.
30.
31.
32.
Chiusa L, Francia di Celle P, Campisi P et al (2006) Prognostic value of quantitative analysis of WT1 gene transcripts in adult acute lymphoblastic leukemia. Haematologica 91(2):270–271PubMed
33.
34.
Barragan E, Cervera J, Bolufer P et al (2004) Prognostic implications of Wilms’ tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 89(8):926–933PubMed
35.
Bergmann L, Miething C, Maurer U et al (1997) High levels of Wilms’ tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90(3):1217–1225PubMed
36.
Trka J, Kalinova M, Hrusak O et al (2002) Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 16(7):1381–1389. doi:10.​1038/​sj.​leu.​2402512 CrossRefPubMed
Metadata
Title
Wilms’ tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome
Authors
Antonia Busse
Nicola Gökbuget
Jan Michael Siehl
Dieter Hoelzer
Stefan Schwartz
Anika Rietz
Eckhard Thiel
Ulrich Keilholz
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 12/2009
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-009-0746-2

Other articles of this Issue 12/2009

Annals of Hematology 12/2009 Go to the issue

Original Article

IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide

Original Article

The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia—a report from the German Registry covering the period from 1998 to 2004

Letter to the Editor

Successful metronomic low-dose cyclophosphamide therapy in an older patient with advanced mucosa-associated lymphoid tissue lymphoma

Original Article

Changes in the MDR1 gene expression after short-term ex vivo therapy with prednisolone have prognostic impact in childhood acute lymphoblastic leukemia

Original Article

Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin’s lymphoma

Original Article

Therapeutic implication of BAL in patients with neutropenia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits